Johnson Matthey (LON:JMAT - Free Report) had its price target lowered by Berenberg Bank from GBX 1,650 ($20.94) to GBX 1,500 ($19.04) in a research report released on Thursday morning, Marketbeat reports. The brokerage currently has a hold rating on the stock.
Johnson Matthey Stock Up 2.8 %
LON JMAT traded up GBX 37 ($0.47) during trading hours on Thursday, reaching GBX 1,367 ($17.35). 84,820,820 shares of the company traded hands, compared to its average volume of 1,291,557. The company has a 50 day moving average of GBX 1,510.09 and a two-hundred day moving average of GBX 1,610.89. The company has a current ratio of 1.45, a quick ratio of 0.76 and a debt-to-equity ratio of 63.15. Johnson Matthey has a 12 month low of GBX 1,318 ($16.73) and a 12 month high of GBX 1,917.07 ($24.33). The stock has a market capitalization of £2.38 billion, a PE ratio of 2,355.91, a PEG ratio of 49,242.50 and a beta of 0.95.
Johnson Matthey Cuts Dividend
The business also recently declared a dividend, which will be paid on Tuesday, February 4th. Investors of record on Thursday, December 5th will be issued a dividend of GBX 22 ($0.28) per share. This represents a dividend yield of 1.47%. The ex-dividend date is Thursday, December 5th. Johnson Matthey's dividend payout ratio is currently 13,275.86%.
Insider Buying and Selling
In other Johnson Matthey news, insider Liam Condon purchased 21 shares of the stock in a transaction on Wednesday, September 18th. The shares were purchased at an average price of GBX 1,598 ($20.28) per share, with a total value of £335.58 ($425.97). Also, insider Stephen Oxley sold 19,554 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of GBX 1,526 ($19.37), for a total transaction of £298,394.04 ($378,768.77). Over the last three months, insiders purchased 7,479 shares of company stock worth $10,057,890. 0.61% of the stock is owned by company insiders.
Johnson Matthey Company Profile
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Read More
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.